MAYARA - CAMPUS SAO LUIS MONTE SÁ

Dr. MAYARA - CAMPUS SAO LUIS MONTE SÁ

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CCCamila Silva da Costa
Camila Silva da Costa
EMEstela Mesquita Marques
Estela Mesquita Marques
JNJessyane Rodrigues Do Nascimento
Jessyane Rodrigues Do Nascimento
VLVICTOR ANTONIO SILVA LIMA
VICTOR ANTONIO SILVA LIMA
RSRalph Santos-Oliveira
Ralph Santos-Oliveira
RGRenato Sonchini Gonçalves
Renato Sonchini Gonçalves
Infectious and Parasitic Diseases (IPD) remain a challenge for medicine due to several interconnected reasons, such as antimicrobial resistance (AMR). American tegumentary leishmaniasis (ATL) is an overlooked IPD causing persistent skin ulcers that are challenging to heal, resulting in disfiguring scars. Moreover, it has the potential to extend from the skin to the mucous membranes of the nose, mouth, and throat in both humans and various animals. Given the limited effectiveness and AMR of current drugs, the exploration of new substances has emerged as a promising alternative for ATL treatment. Arrabidaea brachypoda (DC). Bureau is a native Brazilian plant rich in dimeric flavonoids, including Brachydin (BRA), which displays antimicrobial activity, but still little has been explored regarding the development of therapeutic formulations. In this work, we present the design of a low-cost liquid formulation based on the use of Pluronic F127 for encapsulation of high BRA concentration (LF-B500). The characterization techniques revealed that BRA-loaded F127 micelles are well-stabilized in an unusual worm-like form. The in vitro cytotoxicity assay demonstrated that LF-B500 was non-toxic to macrophages but efficient in the inactivation of forms of Leishmania amazonensis promastigotes with IC50 of 16.06 µg/mL. The results demonstrated that LF-B500 opened a new perspective on the use of liquid formulation-based natural products for ATL treatment.

23 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
FFFelipe Rodrigues Silva Felipe
Felipe Rodrigues Silva Felipe
EJEdson Tobias De Jesus
Edson Tobias De Jesus
MSMAYARA - CAMPUS SAO LUIS MONTE SÁ
MAYARA - CAMPUS SAO LUIS MONTE SÁ
MDMargaret Dawson
Margaret Dawson
TSThaynara Ramalho Santos
Thaynara Ramalho Santos
GSGilmar Silverio da Silva
Gilmar Silverio da Silva
Background/Objectives: The growing threat of antimicrobial resistance (AMR) has inten-sified the search for innovative antimicrobial materials. Herein, we synthesized and characterized zinc bismuthate-based nanocomposites (ZB1 and ZB4) and investigated their antimicrobial efficacy against two Gram-positive bacteria (Staphylococcus aureus and Corynebacterium diphtheriae), one Gram-negative bacterium (Klebsiella pneumoniae), and two fungal pathogens (Cryptococcus neoformans and Candida albicans). Toxicity was further as-sessed using Tenebrio molitor larvae as an alternative model. Methods: Nanocomposites were prepared via a hydrothermal process and characterized using X-ray diffraction (XRD), Raman spectroscopy, Zeta potential, and high-resolution transmission electron microscopy (HR-TEM). Antimicrobial activity was evaluated through disk diffusion as-says coupled with minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) assessments. Results: ZB1 and ZB4 inhibited S. aureus (10.7 ± 1.2 mm and 11.3 ± 1.2 mm), C. diphtheriae (10.7 ± 1.1 mm and 11.3 ± 1.1 mm), and C. neoformans (10.7 ± 1.1 mm and 11.7 ± 2.9 mm), while no inhibition was observed for C. albicans and K. pneumoniae. From MIC and MFC evaluations, ZB1 was effective up to 1000 μg/mL, and ZB4 up to 500 μg/mL. Toxicity assays revealed survival rates of 70% for ZB1 and 60% for ZB4, with no statistically significant differences compared to the control (p = 0.156). Notably, ZB4 is a promising candidate due to its enhanced antimicrobial performance and moderate toxicity. Conclusions: Our findings highlight ZB1 and ZB4 nanocomposites as promising antimicrobial agents, offering new avenues in nanotechnology-driven healthcare solutions aimed at tackling antimicrobial resistance.

1 January 2026 in Journal of the Brazilian Chemical Society
Verified
Journal Article
Closed access
FFFelipe Rodrigues Silva Felipe
Felipe Rodrigues Silva Felipe
EJEdson Tobias De Jesus
Edson Tobias De Jesus
MSMAYARA - CAMPUS SAO LUIS MONTE SÁ
MAYARA - CAMPUS SAO LUIS MONTE SÁ
MDMargaret Dawson
Margaret Dawson
TSThaynara R. Santos
Thaynara R. Santos
GSGilmar S. da Silva
Gilmar S. da Silva
The growing threat of antimicrobial resistance has intensified the search for new antimicrobial materials. In this work, zinc bismuthate-based nanocomposites (ZB1 and ZB4) were synthesized by a hydrothermal method and characterized using X-ray diffraction, Raman spectroscopy, zeta potential and high-resolution transmission electron microscopy. Structural analyses suggested the coexistence of a zinc oxide secondary phase and oxygen vacancies, which may influence the physicochemical and biological behavior of the materials. The antimicrobial activity was evaluated against Staphylococcus aureus, Corynebacterium diphtheriae, Klebsiella pneumoniae, Cryptococcus neoformans, and Candida albicans by disk diffusion. For C. diphtheriae and C. neoformans, additional minimum inhibitory concentration and minimum fungicidal concentration assays were performed. Both nanocomposites inhibited S. aureus, C. diphtheriae, and C. neoformans, while no inhibition was observed for C. albicans and K. pneumoniae. ZB4 exhibited superior antimicrobial activity, with growth inhibition observed up to 500 µg mL-1, whereas ZB1 was effective only at higher concentrations. Toxicity tests using Tenebrio molitor larvae revealed survival rates of approximately 70% for ZB1 and 60% for ZB4 after 10 days, with no statistically significant difference compared to the control. Overall, ZB4 presented promising antimicrobial activity with moderate toxicity, indicating its potential for biomedical applications.